NasdaqGS:ERASBiotechs
Assessing Erasca (ERAS) Valuation After New Pan KRAS Patent Win Through 2043
Patent win puts Erasca’s pan-KRAS program in sharper focus
Erasca (ERAS) has secured a new U.S. patent covering its pan-KRAS inhibitor ERAS-4001 and related compositions through at least 2043. This development tightens protection around its RAS-driven cancer pipeline.
See our latest analysis for Erasca.
The new patent arrives during a strong run in Erasca’s shares, with a 30-day share price return of 36.65% and a 90-day share price return of 334.82%. The 1-year total shareholder return is...